Synagis
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Overview
Synagis is a humanized antibody inhibitor of the RSV fusion (F) protein. By blocking the interaction of the RSV F protein with the cell membrane, Synagis inhibits viral entry into host cells and also prevents cell-to-cell fusion of infected cells. Passive immunization with Synagis is initiated at the start of the RSV season and requires a total of five monthly doses to maintain protection across the entire period.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Synagis : Respiratory syncytial virus (RSV) vaccines
LIST OF FIGURES
9 Figure 1: Synagis for respiratory syncytial virus – SWOT analysis
16 Figure 2: Synagis sales for RSV across the US and five major EU markets, 2016/17–2025/26
LIST OF TABLES
6 Table 1: Synagis drug profile
7 Table 2: Synagis Phase III data in RSV
11 Table 3: Recommendations for palivizumab immunization by national authorities, 2018
17 Table 4: Synagis sales for RSV across the US and five major EU markets, by country ($m), 2016/17–2025/26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Live-attenuated RSV vaccines 
Sign up to the